Join this year's Career Development Workshop designed for both trainees interested in a hepatology career and early-career hepatologists. Participants will explore hepatology training pathways to different career opportunities, ranging from research to community-based practice. Participants will discuss the rewards and challenges of various careers, and strategies to maximize oneâs potential, including finding mentors.
What role does social media, the communications landscape that currently influences everything from politics to pop culture, play in hepatology and healthcare? This program will expose participants to different aspects of social media and encourage discussion ways that social media could advance the science and practice of hepatology.
Alcohol-associated liver disease (ALD) has emerged as a leading indicator of liver disease and the need for organ transplant. Currently, we lack effective pharmacological therapies to improve long-term outcomes in ALD patients, but new research advances are highly encouraging. Join this ALD SIG program for important research updates and to identify unmet clinical needs in ALD patients.
Value-based Arrangements are an increasingly expanding and necessary part of the U.S. healthcare landscape. This program will educate and empower hepatologists to be valuable contributors to the success of these new arrangements and play an active role in developing and implementing beneficial approaches for all patients with liver disease.
What is the role of organ transplantation in the care of acute on chronic liver failure (ACLF)? This program was designed to thoroughly review the management of the ACLF patient awaiting liver transplantation (LT), and to examine recently published data on patient outcomes. Post-LT complications and the evolving role of palliative care in patients listed for LT will be explored.
The COVID-19 pandemic has affected everyone, including patients with liver disease, and the pre- and post-transplant population. At this program, experts discuss the effect of the virus on the liver and treatment options, as well as COVID-19's impact on organ donation and pre-, and post- liver transplant patients in highly affected areas in the United States and Europe. Keep the conversation going! Join us in one of 3 Breakout Sessions immediately following the Transplant Surgery Workshop. Go to the Session Listing within the TLMdX Platform and select Breakout Sessions 1 - 3.
What support and knowledge do clinical practitioners caring for liver patients need in the healthcare system of 2020? This overview session provides a general update on hepatology for practitioners in all clinical environments. Speakers will provide updated information on selected liver disorders that are prevalent, complex and have a significant impact on routine medical practice today.
This lecture will highlight liver disease research advances supported by the National Institute of Diabetes and Digestive and Kidney Diseases, as part of its 70th year shared anniversary with AASLD. Dr. Rodgers will share current research challenges and opportunities, including the COVID-19 pandemic, efforts to address health disparities and include underrepresented populations in the scientific workforce, and the Institute's strategic plan.
What are the latest developments in managing patients with liver disease and cirrhosis? Join this engaging discussion by international experts, who will address management of portal vein thrombosis, interpretation of abnormal iron studies, managing acute kidney injury in hospitalized patients with liver disease, best practices for hepatocellular carcinoma and cholangiocarcinoma screening, and both pharmacologic and non-pharmacologic management of non-alcoholic steatohepatitis.
The COVID-19 patient engagement subcommittee presents patient-centered updates on the current knowledge, practice and recommendations in the care of chronic liver disease in the COVID-19 era at this timely session. Presentations include current data on COVID-19 and the liver, patient-driven case studies, and case discussions of liver disease patients who have recovered from COVID-19.